An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients.

Recruiting now · Phase 2

Conditions studied: Hypertension (HTN)

In brief

The purpose of this extension study is to collect additional safety and efficacy on QCZ484 for hypertensive patients who successfully completed the parent study, CQCZ484A12201 or additional QCZ484 studies as specified in the respective parent study protocols.

Key facts

Study ID

NCT07543120

Run by

Novartis Pharmaceuticals

People needed

323

Starts

2026-05-07

Expected to finish

2031-11-30

Last updated by the study team

2026-07-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Signed informed consent must be obtained prior to participation in the study.
• Successful completion of treatment period on QCZ484 study medication in parent study.
• No significant safety issue that may place participant at safety risk as determined by the Investigator.

You may not qualify if…

• Participants meeting any of the following criteria, may it be pre-existing or developed during the parent study, are not eligible for inclusion in this study:
• Evidence of hepatic disease that would put participant at risk by taking QCZ484 for long term as determined by the Investigator.
• Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia), high-grade atrioventricular (AV) block (e.g., Mobitz type II and third-degree AV block in absence of a pacemaker) developed during the parent study.
• Permanent or persistent atrial fibrillation developed during the parent study.
• Clinically significant valvular heart disease developed during the parent study.
• Acute myocardial infarction (AMI) or unstable angina, or any percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) developed during the parent study. Any history of ischemic or hemorrhagic stroke or transient ischemic attack any time prior to enrollment.
• Other protocol-defined inclusion/exclusion criteria may apply

Where it is running

• NICRs Research Center — Garden Grove, California, United States (enrolling)
• Downtown L A Research Center Inc — Los Angeles, California, United States (enrolling)
• Clinical Research of Brandon LLC — Brandon, Florida, United States (enrolling)
• Entrust Clinical Research — Miami, Florida, United States (enrolling)
• Inpatient Research Clinical LLC — Miami Lakes, Florida, United States (enrolling)
• American Research Centers of FL — Pembroke Pines, Florida, United States (enrolling)
• Cen Exel FCR — Tampa, Florida, United States (enrolling)
• Cardiology Partners Clinical Research Institute — Wellington, Florida, United States (enrolling)
• Javara Research — Fayetteville, Georgia, United States (enrolling)
• Eagle Clinical Research — Chicago, Illinois, United States (enrolling)
• Alliance for Multispecialty Research — Wichita, Kansas, United States (enrolling)
• Anderson Medical Research — Ft. Washington, Maryland, United States (enrolling)
• Oakland Medical Research Center — Troy, Michigan, United States (enrolling)
• Jefferson City Medical Group — Jefferson City, Missouri, United States (enrolling)
• CenExel HRI — Berlin, New Jersey, United States (enrolling)
• Monroe Biomedical Research — Monroe, North Carolina, United States (enrolling)
• Conrad Clinical Research — Edmond, Oklahoma, United States (enrolling)
• Clinical Neuroscience Solutions Inc — Memphis, Tennessee, United States (enrolling)
• Sun Research Institute — San Antonio, Texas, United States (enrolling)
• Novartis Investigative Site — Suita, Osaka, Japan (enrolling)
• Novartis Investigative Site — Chuo Ku, Tokyo, Japan (enrolling)
• Novartis Investigative Site — Chuo-ku, Tokyo, Japan (enrolling)
• Novartis Investigative Site — Shinjuku Ku, Tokyo, Japan (enrolling)
• Novartis Investigative Site — Singapore, Singapore (enrolling)
• Novartis Investigative Site — Singapore, Singapore (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.